Relmada Therapeutics Q1 net loss widens, cash rises

Relmada Therapeutics

12/05/2026 21:22

Overview

US biotech reported Q1 net loss widened to $19.1 mln, EPS at -$0.22

Company ended Q1 with $234 mln in cash and investments after $150 mln private placement

R&D expenses fell yr/yr due to non-recurring 2025 costs, G&A expenses increased

Outlook

Relmada expects to file NDV-01 IND and start Phase 3 RESCUE program in mid-2026

Company anticipates Sepranolone Phase 2 trial initiation in Prader-Willi syndrome in mid-2026

Relmada expects current cash to fund operations through 2029, including NDV-01 Phase 3 completion

Result Drivers

R&D EXPENSE DECREASE - Co said lower R&D expense was due to non-recurring costs for sepranolone acquisition and NDV-01 license in 2025, partially offset by increased costs for new trials and R&D personnel

G&A EXPENSE INCREASE - Higher G&A expense was mainly due to increased compensation costs, partially offset by lower stock-based compensation

Company press release: ID:nGNX4z10tW

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$0.22
Q1 Net Income
-$19.10 mln
Q1 Cash & Investments
$234 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Relmada Therapeutics Inc is $13.00, about 76.6% above its May 11 closing price of $7.36

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)